Cardiology

This pooled analysis reports 7-year cardiovascular outcomes from the open-label extension phases of the FOURIER and ODYSSEY OUTCOMES trials of PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease.

This meta-analysis of 12 randomized controlled trials evaluates the effects of SGLT2 inhibitors on cardiovascular death and heart failure hospitalization across the spectrum of ejection fraction.